CoreComm Internet

Features

Make this your home page

An experimental Alzheimers drug shows promise targeting a different brain protein, new study shows

WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called tau, researchers reported Tuesday. Tau is one part of a toxic duo fueling Alzheimer’s but prior attempts to develop drugs that can target the protein have failed. Two Alzheimer’s drugs, lecanemab and donanemab, try to clear buildup of the better-known amyloid protein and can modestly slow cognitive The of...

Read More
 

----------
Copyright 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

CoreComm is not responsible for content on external sites. Please review the privacy and security policies of each vendor before making online purchases or providing personal information. Forecast Information Provided by AccuWeather.